#ES­MO22: Re­lay Ther­a­peu­tics joins the win­ner's cir­cle this week­end as up­dat­ed can­cer da­ta win ap­plause

PARIS — Re­lay Ther­a­peu­tics had steadi­ly raised the bar ahead of ES­MO for RLY-4008, its bile duct can­cer drug for a nar­row group of pa­tients with FGFR2-al­tered cholan­gio­car­ci­no­ma. And now it’s ar­riv­ing in Paris with an im­proved per­for­mance that ap­pears to pave a di­rect path to a quick ap­proval.

The bot­tom line from its ES­MO ab­stract:

Po­tent ef­fi­ca­cy was ob­served across all dos­es, par­tic­u­lar­ly at the RP2D (70mg QD) with an ORR of 88%. One pt treat­ed at the RP2D had a near-com­plete re­sponse and sub­se­quent tu­mor re­sec­tion with cu­ra­tive in­tent. DOR is not yet ma­ture, with ma­jor­i­ty of re­spons­es on­go­ing. Across all dos­es (N=195), the most com­mon treat­ment-re­lat­ed AEs (TRAEs) were low-grade stom­ati­tis (48%), PPE (46%), and dry mouth (31%). No grade 4/5 TRAEs were ob­served.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER